

National Institute for Health and Care Excellence

Motor Neurone Disease

Stakeholder Comments – Draft Scope

NOTE:		
<p>NICE is unable to accept comments from non-registered organisations or individuals. If you wish your comments to be considered but are not a registered stakeholder, please register via the NICE website or contact the registered stakeholder organisation that most closely represents your interests and pass your comments to them.</p> <p>Please fill in both the ‘stakeholder organisation’ and ‘name of commentator’ fields below in order for your comments to be considered.</p>		
Stakeholder organisation:		The Royal Pharmaceutical Society
Name of commentator:		Miriam Gichuhi
Comment No.	Section number <small>Indicate number or ‘general’ if your comment relates to the whole document</small>	Comments Please insert each new comment in a new row. Please do not paste other tables into this table, as your comments could get lost – type directly into this table
Proformas that are not correctly submitted as detailed in the line above may be returned to you.		
1	Section 4.5.2	<p>The Royal Pharmaceutical Society welcomes the development of a clinical guideline on the assessment and management of motor neurone disease</p> <p>We are pleased that the assessment of the impact of the multidisciplinary team on overall care has been included as part of the review questions. We would recommend as part of the review and guidance that consideration is given to how individual healthcare professionals, including pharmacists working within the community, might be involved at each stage in the care pathway and also how they might work together to improve patient outcomes. As experts in medicines, pharmacists provide advice on how to take medicines, adverse effects, possible interactions and cautions, to raise patients’ and carers’ awareness and understanding of the condition and therapy. Pharmacists are ideally placed to form part of these teams.</p>
2		

PLEASE NOTE: The Institute reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of the Institute, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.

3		
4		
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		

Please add extra rows as needed.

Please email this form to: mnd@nice.org.uk

Closing date: 5pm on 13 December 2013.

PLEASE NOTE: The Institute reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of the Institute, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.